Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology

The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies. The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies. Sanofi and Regeneron have been working together for more than two decades, marking one of the longest and most successful pharma pair-ups in the industry. Credit: Grand Warszawski/Shutterstock.com. Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their pipeline horizon – the companies have agreed to expand their partnership that will see the two work together on four new antibodies in a deal rising…

Source: Pharmaceutical Technology